Review Article
FOXO Transcriptional Factors and Long-Term Living

Ghulam Murtaza,1,2,3 Abida Kalsoom Khan,4 Rehana Rashid,4 Saiqa Muneer,5 Syed Muhammad Farid Hasan,6 and Jianxin Chen1

1Beijing University of Chinese Medicine, Beisanhuan East Road, Beijing 100029, China
2Department of Pharmacy, COMSATS Institute of Information Technology, Abbottabad, Pakistan
3Institute of Automation, Chinese Academy of Sciences, Beijing, China
4Department of Chemistry, COMSATS Institute of Information Technology, Abbottabad, Pakistan
5Department of Pharmacy, University of Lahore, Lahore, Pakistan
6Department of Pharmaceutics, Faculty of Pharmacy and Pharmaceutical Sciences, University of Karachi, Karachi, Pakistan

Correspondence should be addressed to Ghulam Murtaza; gmdogar356@gmail.com and Jianxin Chen; cjx@bucm.edu.cn

Received 6 May 2017; Accepted 21 June 2017; Published 15 August 2017

Copyright © 2017 Ghulam Murtaza et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Several pathologies such as neurodegeneration and cancer are associated with aging, which is affected by many genetic and environmental factors. Healthy aging conceives human longevity, possibly due to carrying the defensive genes. For instance, FOXO (forkhead box O) genes determine human longevity. FOXO transcription factors are involved in the regulation of longevity phenomenon via insulin and insulin-like growth factor signaling. Only one FOXO gene (FOXO DAF-16) exists in invertebrates, while four FOXO genes, that is, FOXO1, FOXO3, FOXO4, and FOXO6 are found in mammals. These four transcription factors are involved in the multiple cellular pathways, which regulate growth, stress resistance, metabolism, cellular differentiation, and apoptosis in mammals. However, the accurate mode of longevity by FOXO factors is unclear until now. This article describes briefly the existing knowledge that is related to the role of FOXO factors in human longevity.

1. Introduction

Aging is related to the age-dependent impaired functioning of the cells, tissues, organs, and organ systems [1, 2]. This impairment leads to chronic pathologies including neurodegeneration, cardiovascular diseases, and cancer. Owing to these age-associated diseases, the researchers have always been interested in understanding the aging process and delaying the aging for human longevity [3, 4].

Healthy aging is a complex phenotype and an interplay of genetic and environmental factors such as food, exercise, and habits [5, 6]. However, rather than environmental factors, the contribution of genetic factors towards healthy aging is more significant. Thus, intensive studies have been done to investigate the genetic variants associated to human longevity.

Since health status affects the lifespan, the development of chronic diseases is delayed in the long-lived individuals [7–9]. These individuals could be the carriers of the defensive genes, which may be involved in body’s defense against vulnerable moieties such as reactive oxygen species [10]. FOXO gene is one of the most crucial defensive genes that are known for ameliorating lifespan [4, 11–16]. Thus, aging can be considered an evolutionary process that is modulated by genetic programming and biochemical processes [17–20]. Figure 1 illustrates various modes of aging as studied in different organisms [18].

As observed in an animal study, the first ever documented mode of aging was deregulated nutrient sensing that involved the insulin and insulin-like growth factor- (IGF-) 1 signaling (IIS) pathway [21]. In IIS pathway, IGF-1 and insulin share and stimulate the same signaling pathways [22–24]. Thus, food that is an important environmental factor involved in IIS pathways must be cautiously used to achieve human longevity [23, 25, 26]. Other components of nutrient sensing pathways are the sirtuins, AMP (adenosine
monophosphate) kinase, and the kinase mTOR (molecular target of rapamycin) [21].

2. FOXO Transcription Factors

The IIS pathway is highly influenced by the FOXO proteins [27, 28]. Forkhead box (FOX) transcription factor family was named after the Drosophila forkhead gene. The FOX family contains nineteen subfamilies of FOX genes, FOXA-FOXS, and is described by a highly conserved, winged-helix DNA-binding domain and the forkhead motif [29–32]. Other (O) subfamily of FOX, FOXO, is conserved from Caenorhabditis elegans (C. elegans) to mammals; only one FOXO gene exists in the invertebrates while mammals have 4 FOXO genes, FOXO1, FOXO3, FOXO4, and FOXO6 [29, 33, 34]. The alternate names FKHR, FKHR1, and AFX have been used for FOXO1, FOXO3, and FOXO4, respectively [35]. FOXO1, FOXO4, and FOXO6 are overexpressed in the adipose, skeletal, and nervous tissues, respectively, while FOXO3 are excessively found in the spleen, stomach, intestine, kidney, and cardiac tissues [36]. These four genes are involved in the multiple cellular pathways, which regulate proliferation (FOXO1, FOXO3, and FOXO4), oxidative stress resistance (FOXO1 and FOXO3), metabolism (FOXO1 and FOXO3), cellular differentiation (FOXO3), inflammation (FOXO1, FOXO3, and FOXO4), aging (FOXO1, FOXO3, and FOXO4), and apoptosis (FOXO1, FOXO3, and FOXO4) in mammals [29–32, 37–40]. However, the involvement of these four genes in human longevity is still unrevealed.

FOXO proteins act as transcription activators and are suppressed by the IIS pathway [31, 37–40]. Concisely, P13K-AKT-mediated signaling pathway is activated by IGF-1 or insulin. It leads to the serine/threonine kinase AKT-induced phosphorylation of FOXO factors resulting in its nuclear exclusion and inhibition of FOXO-dependent transcription of target genes [41]. On the other hand, cellular stress leads to translocation of FOXO factors into the nucleus and activation of FOXO-dependent transcription. Besides phosphorylation, other posttranslational modifications including ubiquitination and methylation also influence the FOXO-dependent transcription [39, 40]. Thus, the FOXO posttranslational modifications lead to the aggregation of particular FOXO-dependent moieties that regulate various FOXO-dependent gene expressions [39, 42, 43]. In this article, various modes of human longevity involving FOXO transcription factors have been suggested.

3. Role of FOXO in Autophagy

The genes which mediate the intracellular clearance through autophagy and the ubiquitin-proteasome system are also regulated by FOXO factors [40, 44, 45]; thus, it can be suggested that FOXOs function as prolongevity factors. Starvation-induced defects in autophagy and the ubiquitin-proteasome system have been linked with the frailty and early aging (Figure 2) [46–48]. In addition, the genes which mediate the autophagy and mitophagy in muscle cells are also regulated by FOXO factors; it helps the tissues to adapt to starvation [49–51]. Moreover, Webb and Brunet [40] observed the activation of autophagy mechanisms by FOXO1 and FOXO3 in renal tubular cells, neurons, and cardiomyocytes. Since, FOXO factors play a role in proteasome-mediated degradation of short-lived cellular organelles and proteins, a suppressed proteosomal activity results in the aggregation of degraded proteins in the heart, liver, and muscle leading to aging [52, 53]. Additionally, the malfunctioned ubiquitin-proteasome system is a direct or indirect cause of various neurodegenerative diseases, for instance, Alzheimer’s disease [40, 54, 55]. FOXO factors act on the neurodegenerative system via the upregulated ubiquitin ligases and by mediating the proteasome’s composition [56–59]. However, the direct influence of proteostasis provoked by FOXO factors in mammals is not still disclosed.

4. Role of FOXO in Oxidative Stress

Antioxidant role of FOXO is its most crucial function. Since reactive oxygen species (ROS) produce conserved deteriorating effect on cells and induce aging, FOXOs could be used to
influence aging by ameliorating the antioxidant potential of cells [60, 61]. ROS act as second messengers in various signaling pathways. An equilibrium in the production and degradation of ROS is necessary for normal cellular functioning, while imbalanced level of ROS results in abnormal functioning of the cells leading to various pathologies such as neurodegenerative diseases and cancer. Oxidative stress regulates FOXO factors, either through detection of cellular redox potential or modifying the upstream FOXO regulatory pathways [62, 63]. Normally, cellular detoxification keeps ROS level in normal range. An impaired cellular detoxification results in oxidative stress. Manganese superoxide dismutase (MnSOD), catalase, and GADD45 are major detoxification enzymes that are regulated by FOXOs [60, 64]. Hence, the inactivation of FOXOs result in the ROS built-up in the cells; it leads to various cellular abnormalities such as the compromised proliferation of normal stem cells but quick proliferation of transformed cells [65, 66].

5. Role of FOXO in Stem Cells

FOXO factors are known to be involved in stem cell biology. Aging is characterized with disequilibrium between removal and regeneration of cells in tissues, since the regeneration capability of adult stem cells is decreased with aging. Knockout hematopoietic stem cell (HSC) mice (mice with FOXO1/3/4-deficient hematopoietic stem cells) showed apoptosis of HSCs as well as termination of repopulation of HSCs. Likewise, FOXO3-deficient mice illustrated the reduced potential of regeneration of cells [67]. The deletion of FOXO factor could lead to exhaustion of the respective stem cell pool [68]. Surprisingly, the HSC compartment was restored in FOXO-deficient mice treated with an antioxidant N-acetylcyesteine, proposing that stem cells are disturbed by accumulation of ROS. This finding supports the hypothesis that oxidative stress contribute primarily to aging, while malfunctioned adult stem cells have secondary significance in this context [69]. Besides playing a role in adult stem cells, FOX factors mediate the expression of OCT4 and SOX2 factors associated with stemness. Similarly, FOXO1 factors are pluripotent for human embryonic stem cells (ESC), and the ortholog FOXO1 plays similar role in mouse ESCs [70].

6. FOXO Factors and Long-Term Living

This review article narrates a summary of the prevalent knowledge that is associated to the role of FOXO factors in extending human lifespan. Until now, no study describes
the exact mode of action of FOXOs in human aging. However, some studies on various populations narrate the possible role of FOXO factors in human longevity.

The older the age, larger is the contribution of genetics in lifespan stating genetics as a function of human longevity. Thus, genetics is the basic parameter that discriminates the average-lived population from the centenarians [1, 2, 71, 72]. Thus, the centenarians are rich in specific alleles, which possibly represent the genes contributing to human longevity. These genes are therefore extensively being investigated in current years.

First study of this type narrated the association of human longevity with FOXO3A [73]. This study was performed on 4 genes named as FOXO1A, FOXO3A, SIRT1, and COQ7 and one SNP, named as rs2764264, in long-lived American males of Japanese origin. Only FOXO3A and rs2764264 were observed to have association with human longevity among the studied genes and SNPs [73]. The incidence rate of age-associated pathologies such as cancer and neurodegenerative and cardiovascular diseases in these individuals was also lower than control group. The control group was eleven years younger than test. The significantly lower level of insulin in the control group was also due to the same allele [73].

Subsequently, same association was found in male centenarians from Italy [11], Germany [12], and Denmark [13]. In an Italian study, rs2802288 exhibited the maximum allelic relationship-minor allele frequency. All three studies described the significant association between FOXO3 polymorphism and human longevity. While, the Danish study proposed four new single nucleotide polymorphisms (SNPs) (named as rs9400239, rs2764264, rs4797744, and rs13217795) associated with human longevity [13].

In other study, two SNPs from FOXO1A (rs2755209 and rs2755213) and three from FOXO3A (rs4946936, rs2802292, and rs2253310) were analyzed in Chinese centenarians [74]. All the six SNPs were positively and gender-independently linked with long-term survival, except two SNPs from FOXO1A that were negatively linked with longevity in female subjects [74]. The conclusion of study states that there is strong association between FOXO1A and long lifespan in females showing the influence of gender in genetic association to human longevity [74]. Another study in Chinese population reported the gender involvement in the impact of FOXO1A and FOXO3A SNPs independently on human longevity [75–77]. Similar finding showing the importance of genetics in the IIS pathway in long-lived Jews and people of Italy, Japan, and Netherlands has also been reported [78–81]. In addition, human longevity has also been found to be associated with other five FOXO3A SNPs (named as rs2802288, rs2802292, rs1935949, rs13217795, and rs2764264) [15]. Among these five SNPs, rs2802292 and rs2764264 polymorphisms were observed in males only.

The combined effect of FOXO3A and APOE on long-term living has also been reported [2, 16, 82]. Additionally, an increase in the activity of daily life and decrease in the risk of bone fracture in individuals with FOXO3A SNPs were found in long-lived Danish individuals [14]. Conclusively, there is remarkable association between human longevity and FOXO3A SNPs as evident from above cited studies conducted in various populations. However, the translation of FOXO3 gene sequences into phenotypic features that facilitate a long-term living is still unrevealed. Moreover, rather than associating with known SNPs, FOXO3A alleles related to long-term living act as introns [2, 72, 83]. It proposes that these SNPs are expected to influence FOXO3A without affecting protein functionality.

7. Prediction of Mechanisms of FOXO in Long-Term Living

Network pharmacology is a multidisciplinary field that integrates different scientific concepts such as systems biology, cheminformatics, and bioinformatics to explore various novel bioactivities from network-based analysis. For instance, network pharmacology helps us to study gene characteristics and its functions [84], identify therapeutic targets, and explore the mode of action of various drugs [85]. Thus, network pharmacology is used here to predict the possible modes of action of FOXOs in human longevity.

STITCH 4.0 database (http://stitch.embl.de/) [86] has been used to retrieve targets (confidence score >0.4) of FOXO1, FOXO3, FOXO4, and FOXO6 in the form of protein-protein network (Supplementary data, Figure 3, Table 1 available online at https://doi.org/10.1155/2017/3494289). These protein targets were fetched into Cytoscape, and protein-protein interaction network was constructed to visualize the functionality-associated genes. The functional enrichment analysis was conducted by using the gene ontology terms (GO terms) for annotation of the biological functions of FOXO-related targets. Subsequently, Cytoscape plug-in ClueGO [87] was utilized to analyze FOXO-mediated biological process term (BP term) to explore the biological importance of the specific targets linked to FOXO1, FOXO3, and FOXO4. Overall, the significant enrichment of 14, 16, and 7 GO terms was achieved for FOXO1, FOXO3, and FOXO4 (Supplementary data, Figure 4, Table 2). The effect of FOXOs on these BPs has been reported by some investigators. FOXOs are mainly involved in the regulation of metabolism, regulation of reactive species, and regulation of cell cycle arrest and apoptosis. FOXO1 regulates adipogenesis, gluconeogenesis, and glycolysis. Mechanistically, the unphosphorylated FOXO1 binds to the insulin response sequence present in the promoter region of G6P (glucose-6 phosphatase) in the nucleus [88]. It leads to the accelerated transcription resulting in the enhanced production of glucose in the liver. After Akt-mediated phosphorylation, FOXO1 is transferred to the cytoplasm and undergoes ubiquitination and degradation. It leads to the decreased production of glucose in the liver via decreased transcription of G6P leading to the decreased rate of gluconeogenesis and glycogenolysis [89]. Adipogenesis is negatively regulated by FOXO1 through its binding to the promoter region of PPARG (peroxisome proliferator-activated receptor gamma) and inhibiting its transcription [90]. It results in the FOXO1-mediated inhibition of adipogenesis [91]. The initiation of adipogenesis requires the increased levels of PPARG [92, 93]. Moreover, FOXO1...
functions as an association between transcription and insulin-mediated metabolic control; thus, FOXO1 is a promising genetic target to manage type 2 diabetes.

FOXO3 probably induces apoptosis either upregulating the genes needed for cell death [94] or downregulating the antiapoptotic factors [95]. In addition, FOXO3 has been found to regulate Notch signaling pathway during the regeneration of muscle stem cells [96]. Moreover, antioxidants are thought to be upregulated by FOXO3 to protect human health from oxidative stress. Additionally, FOXO3 is documented to suppress tumour [97]. Thus, tumour development may occur if FOXO3 is deregulated. Most importantly, FOXO3 are described to play a role in long-term living [12].

FOXO4 is involved in the regulation of various pathways associated to apoptosis, longevity, cell cycle, oxidative stress, and insulin signaling. FOXO4 are associated with longevity through IIS pathway [98, 99]. Finally, mutation-triggered Akt phosphorylation results in the inactivated FOXO4 [100]. It deregulates cell cycle and activates kinase inhibitor involved in cell cycle [101, 102]. It leads to the prevention of tumour progress into G1. These biological processes make us better understand the modes of action of FOXOs.

8. Conclusions

In current years, the rigorous research attention has been focused on the role of FOXO transcription factors in human longevity. In different animal models, numerous studies have been conducted to investigate the signaling pathways involved in the regulation of the FOXO factors. Moreover, the effect of FOXO-mediated processes on the cellular, tissue, or organism level functions has also been discussed. As a result, a pleiotropic nature of FOXOs’ effect on longevity is established, since FOXOs participate in a number of cellular functions, including growth, stress resistance, metabolism, cellular differentiation, and apoptosis. From the above discussion, numerous strategies for future research can be predicted. For instance, the triggering of FOXO-mediated processes in the tissues with metabolically different features can be valuable to explore the mechanism of FOXO-mediated longevity. In addition, the human FOXO sequence variations and their effect on the resulting proteins should be studied, the possible findings can also reveal the underlying mechanisms of FOXO-induced health aging. The delay in age-related pathologies including cancer and neurodegenerative diseases and living long life depends on the control of morbidity. It is therefore an exciting area of study to investigate the antiaging compounds; however, their testing in clinical setup would need age markers to assess aging rate. Owing to the potential effect of FOXOs on health issues, the future therapies could be based on the FOXOs.

Conflicts of Interest

There is no conflict of interest among authors over contents of this article.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (Grant no. 8152051), Beijing Nova Program (XX2013032), and President’s International Fellowship Initiative (PIFI), Chinese Academy of Sciences (CAS), China (Project no. 2016PT009).

References

[1] P. Sebastiani and T. T. Perls, “The genetics of extreme longevity: lessons from the new England centenarian study,” *Frontiers in Genetics*, vol. 3, p. 277, 2012.
[2] A. R. Brooks-Wilson, “Genetics of healthy aging and longevity,” *Human Genetics*, vol. 132, pp. 1323–1338, 2013.
[3] G. Atzmon, C. Schechter, W. Greiner, D. Davidson, G. Rennert, and N. Barzilai, “Clinical phenotype of families with longevity,” *Journal of the American Geriatrics Society*, vol. 52, pp. 274–277, 2004.
[4] B. J. Wilcox, D. C. Wilcox, Q. He, J. D. Curb, and M. Suzuki, “Siblings of Okinawan centenarians share lifelong mortality advantages,” *The Journals of Gerontology Series A: Biological Sciences and Medical Sciences*, vol. 61, pp. 345–354, 2006.
[5] K. Christensen, T. E. Johnson, and J. W. Vaupel, “The quest for genetic determinants of human longevity: challenges and insights,” *Nature Reviews Genetics*, vol. 7, pp. 436–448, 2006.
[6] N. A. Bishop and L. Guarente, “Genetic links between diet and lifespan: shared mechanisms from yeast to humans,” *Nature Reviews Genetics*, vol. 8, pp. 835–844, 2007.
[7] J. F. Fries, “Aging, natural death, and the compression of morbidity,” *The New England Journal of Medicine*, vol. 303, pp. 130–135, 1980.
[8] R. Hitt, Y. Young-Xu, M. Silver, and T. Perls, “Centenarians: the older you get, the healthier you have been,” *Lancet*, vol. 354, p. 652, 1999.
[9] S. L. Andersen, P. Sebastiani, D. A. Dworkis, L. Feldman, and T. T. Perls, “Health span approximates life span among many supercentenarians: compression of morbidity at the approximate limit of life span,” *The Journals of Gerontology Series A: Biological Sciences and Medical Sciences*, vol. 67, pp. 395–405, 2012.
[10] M. Beekman, C. Nederstigt, H. E. Suchiman et al., “Genome-wide association study (GWAS)-identified disease risk alleles do not compromise human longevity,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, pp. 18046–18049, 2010.
[11] C. V. Anselmi, A. Malovini, R. Roncarati et al., “Association of the FOXO3A locus with extreme longevity in a southern Italian centenarian study,” *Rejuvenation Research*, vol. 12, pp. 95–104, 2009.
[12] F. Flachsbart, A. Caliebe, R. Kleindorp et al., “Association of FOXO3A variation with human longevity confirmed in German centenarians,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 106, pp. 2700–2705, 2009.
[13] M. Soerensen, S. Dato, K. Christensen et al., “Replication of an association of variation in the FOXO3A gene with human longevity using both case-control and longitudinal data,” *Aging Cell*, vol. 9, pp. 1010–1017, 2010.
[14] M. Soerensen, M. Nygaard, S. Dato et al., “Association study of FOXO3A SNPs and aging phenotypes in Danish oldest-old individuals,” Aging Cell, vol. 14, pp. 60–66, 2015.

[15] J. M. Bao, X. L. Song, Y. Q. Hong et al., “Association between FOXO3A gene polymorphisms and human longevity: a meta-analysis,” Asian Journal of Andrology, vol. 16, pp. 446–452, 2014.

[16] L. Broer, A. S. Buchman, J. Deelen et al., “GWAS of longevity in CHARGE consortium confirms APOE and FOXO3 candidacy,” The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, vol. 70, pp. 110–118, 2015.

[17] C. J. Kenyon, “The genetics of aging,” Nature, vol. 464, pp. 504–512, 2010.

[18] C. Lopez-Otin, M. A. Blasco, L. Partridge, M. Serrano, and G. Kroemer, “The hallmarks of aging,” Cell, vol. 153, pp. 1194–1217, 2013.

[19] M. V. Blagosklonny, “Aging is not programmed: genetic pseudo-program is a shadow of developmental growth,” Cell Cycle, vol. 12, pp. 3736–3742, 2013.

[20] M. V. Blagosklonny, “Rapamycin extends life- and health span because it slows aging,” Aging (Albany, New York), vol. 5, pp. 592–598, 2013.

[21] C. Kenyon, “The plasticity of aging: insights from long-lived mutants,” Cell, vol. 120, pp. 449–460, 2005.

[22] M. Tatar, A. Kopelman, D. Epstein, M. P. Tu, C. M. Yin, and R. S. Garofalo, “A mutant drosophila insulin receptor homolog that extends life-span and impairs neuroendocrine function,” Science (New York, New York), vol. 292, pp. 107–110, 2001.

[23] L. Fontana, L. Partridge, and V. D. Longo, “Extending healthy life span – from yeast to humans,” Science, vol. 328, pp. 321–326, 2010.

[24] E. M. Mercken, S. D. Crosby, D. W. Lamming et al., “Calorie restriction in humans inhibits the PI3K/AKT pathway and induces a younger transcription profile,” Aging Cell, vol. 12, pp. 645–651, 2013.

[25] R. J. Colman, R. M. Anderson, S. C. Johnson et al., “Caloric restriction delays disease onset and mortality in rhesus monkeys,” Science (New York, New York), vol. 325, pp. 201–204, 2009.

[26] J. A. Mattison, G. S. Roth, T. M. Beasley et al., “Impact of caloric restriction on health and survival in rhesus monkeys from the NIA study,” Nature, vol. 489, pp. 318–321, 2012.

[27] C. Kenyon, J. Chang, E. Gensch, A. Rudner, and R. Tabtiang, “A C. elegans mutant that lives twice as long as wild type,” Nature, vol. 366, pp. 461–464, 1993.

[28] X. C. Dong, K. D. Copps, S. Guo et al., “Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation,” Cell Metabolism, vol. 8, pp. 65–76, 2008.

[29] G. Tuteja and K. H. Kaestner, “Forkhead transcription factors I,” Cell, vol. 130, p. 1160, 2007.

[30] G. Tuteja and K. H. Kaestner, “Forkhead transcription factors II,” Cell, vol. 131, p. 192, 2007.

[31] F. Zanella, W. Link, and A. Carnero, “Understanding FOXO, new views on old transcription factors,” Current Cancer Drug Targets, vol. 10, pp. 135–146, 2010.

[32] E. C. Genin, N. Caron, R. Vandebosch, L. Nguyen, and B. Malgrange, “Concise review: forkhead pathway in the control of adult neurogenesis,” Stem Cells, vol. 32, pp. 1398–1407, 2014.

[33] K. H. Kaestner, W. Knochel, and D. E. Martinez, “Unified nomenclature for the winged helix/forkhead transcription factors,” Genes & Development, vol. 14, pp. 142–146, 2000.

[34] S. Hannenhalli and K. H. Kaestner, “The evolution of fox genes and their role in development and disease,” Nature Reviews Genetics, vol. 10, pp. 233–240, 2009.

[35] R. Martins, G. J. Lithgow, and W. Link, “Long live FOXO: unraveling the role of FOXO proteins in aging and longevity,” Aging Cell, vol. 15, pp. 196–207, 2016.

[36] Z. Fu and D. J. Tindall, “FOXOs, cancer and regulation of apoptosis,” Oncogene, vol. 27, no. 16, p. 2312, 2008.

[37] S. T. Henderson and T. E. Johnson, “Daf-16 integrates developmental and environmental inputs to mediate aging in the nematode Caenorhabditis elegans,” Current Biology, vol. 11, pp. 1975–1980, 2001.

[38] K. Lin, H. Hsin, N. Libina, and C. Kenyon, “Regulation of the Caenorhabditis elegans longevity protein DAF-16 by insulin/IGF-1 and germline signaling,” Nature Genetics, vol. 28, pp. 139–145, 2001.

[39] D. R. Calnan and A. Brunet, “The FoxO code,” Oncogene, vol. 27, pp. 2276–2288, 2008.

[40] A. E. Webb and A. Brunet, “FOXO transcription factors: key regulators of cellular quality control,” Trends in Biochemical Sciences, vol. 39, pp. 159–169, 2014.

[41] C. T. Murphy, S. A. McCarroll, C. I. Bargmann et al., “Genes that act downstream of DAF-16 to influence the lifespan of Caenorhabditis elegans,” Nature, vol. 424, pp. 277–283, 2003.

[42] E. L. Greer, P. R. Oskoui, M. R. Banko et al., “The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor,” The Journal of Biological Chemistry, vol. 282, pp. 30107–30119, 2007.

[43] R. Hill, R. K. Kalathur, S. Callejas et al., “A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genes,” Breast Cancer Research, vol. 16, p. 482, 2014.

[44] J. F. Morley, H. R. Brignull, J. J. Weyers, and R. I. Morimoto, “The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, pp. 10417–10422, 2002.

[45] A.-L. Hsu, C. T. Murphy, and C. Kenyon, “Regulation of aging and age-related disease by DAF-16 and heat-shock factor,” Science (New York, New York), vol. 300, pp. 1142–1145, 2003.

[46] F. Pickford, E. Masliah, M. Britschi et al., “The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice,” The Journal of Clinical Investigation, vol. 118, pp. 2190–2199, 2008.

[47] E. Masiero, L. Agatea, C. Mammucari et al., “Autophagy is required to maintain muscle mass,” Cell Metabolism, vol. 10, pp. 507–515, 2009.

[48] J. H. Lee, A. V. Budanov, E. J. Park et al., “Sestrin as a feedback inhibitor of TOR that prevents age-related pathologies,” Science (New York, New York), vol. 327, pp. 1223–1228, 2010.

[49] J. Zhao, J. J. Brault, A. Schild et al., “FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells,” Cell Metabolism, vol. 6, pp. 472–483, 2007.
A.-L. Bulteau, L. I. Szweda, and B. Friguet, A. D. Husom, E. A. Peters, E. A. Kolling, N. A. Fugere, L. V. A. Sengupta, J. D. Molkentin, and K. E. Yutzey, F. Demontis and N. Perrimon, "FOXO4/E-BP signaling in drosophila muscles regulates organism-wide proteostasis during aging," Cell, vol. 143, pp. 813–825, 2010.

A.-L. Bulteau, L. I. Szveda, and B. Friguet, "Age-dependent declines in proteasome activity in the heart," Archives of Biochemistry and Biophysics, vol. 397, pp. 298–304, 2002.

A. D. Husom, E. A. Peters, E. A. Kolling, N. A. Fugere, L. V. Thompson, and D. A. Ferrington, "Altered proteasome function and subunit composition in aged muscle," Archives of Biochemistry and Biophysics, vol. 421, pp. 67–76, 2004.

A. Ciechanover and P. Brundin, "The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg," Neuron, vol. 40, pp. 427–446, 2003.

E. A. Kikis, T. Gidalevitz, and R. I. Morimoto, "Protein homeostasis in models of aging and age-related conformational disease," Advances in Experimental Medicine and Biology, vol. 694, pp. 138–159, 2010.

M. Sandri, J. Lin, C. Handschin et al., "PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, pp. 16260–16265, 2006.

T. N. Stitt, D. Drujan, B. A. Clarke et al., "The IGF-1/Pi3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors," Molecular Cell, vol. 14, pp. 395–403, 2004.

D. Vilchez, L. Boyer, I. Morantte et al., "Increased proteasome activity in human embryonic stem cells is regulated by PSMD11," Nature, vol. 489, pp. 304–308, 2012.

G. A. Walker and G. J. Lithgow, "Lifespan extension in C. elegans by a molecular chaperone dependent upon insulin-like signals," Aging Cell, vol. 2, pp. 131–139, 2003.

G. J. Kops, T. B. Dansen, P. E. Polderman et al., "Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress," Nature, vol. 419, pp. 316–321, 2002.

P. Storz, "Forkhead homeobox type O transcription factors in the responses to oxidative stress," Antioxidants & Redox Signaling, vol. 14, pp. 593–605, 2011.

A. Eijkelenboom and B. M. Burgering, "FOXOs: signalling integrators for homeostasis maintenance," Nature Reviews Molecular Cell Biology, vol. 14, pp. 83–97, 2013.

M. Putker, T. Madl, H. R. Vos et al., "Redox-dependent control of FOXO/DAF-16 by transportin-1," Molecular Cell, vol. 49, pp. 730–742, 2013.

S. Nemoto and T. Finkel, "Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway," Science, vol. 295, pp. 2450–2452, 2002.

Z. Tothova, R. Kollipara, B. J. Huntly et al., "FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress," Cell, vol. 128, pp. 325–339, 2007.

K. Tsuchiya, M. Westerterp, A. J. Murphy et al., "Expanded granulocyte/monocyte compartment in myeloid specific triple FoxO knockout increases oxidative stress and accelerates atherosclerosis in mice," Circulation Research, vol. 112, pp. 992–1003, 2013.

K. Miyamoto, K. Y. Araki, K. Naka et al., "Foxo3a is essential for maintenance of the hematopoietic stem cell pool," Cell Stem Cell, vol. 1, pp. 101–112, 2007.

Z. Tothova and D. G. Gilliland, "FOXO transcription factors and stem cell homeostasis: insights from the hematopoietic system," Cell Stem Cell, vol. 1, pp. 140–152, 2007.

L. B. Boyette and R. S. Tuan, "Adult stem cells and diseases of aging," Journal of Clinical Medicine, vol. 3, pp. 88–134, 2014.

X. Zhang, S. Yalcin, D. F. Lee et al., "FOXO1 is an essential regulator of pluri potency in human embryonic stem cells," Nature Cell Biology, vol. 13, pp. 1092–1099, 2011.

J. V. Hjelmberg, I. Iachine, A. Skythte et al., "Genetic influence on human lifespan and longevity," Human Genetics, vol. 119, pp. 312–321, 2006.

J. M. Murabito, R. Yuan, and K. L. Lunetta, "The search for longevity and healthy aging genes: insights from epidemiological studies and samples of long-lived individuals," The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, vol. 67, pp. 470–479, 2012.

B. J. Wilcox, T. A. Donlon, Q. He et al., "FOXO3A genotype is strongly associated with human longevity," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, pp. 13987–13992, 2008.

Y. Li, W.-J. J. Wang, H. Cao et al., "Genetic association of FOXO1A and FOXO3A with longevity trait in Han Chinese populations," Human Molecular Genetics, vol. 18, pp. 4897–4904, 2009.

Y. Zeng, L. Cheng, H. Chen et al., "Effects of FOXO1A genotypes on longevity: a biodemographic analysis," The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, vol. 65, pp. 1285–1299, 2010.

N. Li, H. Luo, X. Liu et al., "Association study of polymorphisms in FOXO3, AKT1 and IGF-2R genes with human longevity in a Han Chinese population," Oncotarget, vol. 7, pp. 23–32, 2016.

L. Sun, C. Hu, C. Zheng et al., "FOXO3 variants are beneficial for longevity in southern Chinese living in the Red River basin: a case-control study and meta-analysis," Scientific Reports, vol. 5, p. 9852, 2015.

T. Kojima, H. Kamei, T. Aizu et al., "Association analysis between longevity in the Japanese population and polymorphic variants of genes involved in insulin and insulin-like growth factor I signaling pathways," Experimental Gerontology, vol. 39, pp. 1595–1598, 2004.

M. Kunings, M. L. Putters, R. G. J. Westendorp, P. E. Slagboom, and D. Heemstvan, "SIRT1 gene, age-related diseases, and mortality: the Leiden 85-plus study," The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, vol. 62, pp. 960–965, 2007.

Y. Suh, G. Atzmon, M.-O. Cho et al., "Functionally significant insulin-like growth factor I receptor mutations in centenarians," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, pp. 3438–3442, 2008.

L. Pawlikowska, D. Hu, S. Huntsman et al., "Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity," Aging Cell, vol. 8, pp. 460–472, 2009.

H. E. Wheeler and S. K. Kim, "Genetics and genomics of human aging," Philosophical Transactions of the Royal Society of London, Series B: Biological Sciences, vol. 366, pp. 43–50, 2011.
[83] T. A. Donlon, J. D. Curb, Q. He et al., “FOXO3 gene variants and human aging: coding variants may not be key players,” The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, vol. 67, pp. 1132–1139, 2012.

[84] K. Fang, H. Zhao, C. Sun et al., “Exploring the metabolic network of the epidemic pathogen Burkholderia cenocepaica J2315 via genome-scale reconstruction,” BMC Systems Biology, vol. 5, p. 83, 2011.

[85] L. M. Overton, S. Graham, K. A. Gould et al., “Global network analysis of drug tolerance, mode of action and virulence in methicillin-resistant S. aureus,” BMC Systems Biology, vol. 5, p. 68, 2011.

[86] X. Yao, H. Hao, Y. Li, and S. Li, “Modularity-based credible prediction of disease genes and detection of disease subtypes on the phenotype-gene heterogeneous network,” BMC Systems Biology, vol. 5, p. 79, 2011.

[87] G. Bindea, B. Mlecnik, H. Hackl et al., “ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks,” Bioinformatics, vol. 25, pp. 1093–1093, 2009.

[88] R. Bouchi, K. S. Foo, H. Hua et al., “FOXO1 inhibition yields functional insulin-producing cells in human gut organoid cultures,” Nature Communications, vol. 5, p. 4242, 2014.

[89] U. B. Pajvani, C. J. Shawber, V. T. Samuel et al., “Inhibition of notch signaling ameliorates insulin resistance in a FoxO1-dependent manner,” Nature Medicine, vol. 17, no. 8, pp. 961–967, 2011.

[90] J. J. Kim, P. Li, J. Huntley, J. P. Chang, K. C. Arden, and J. M. Olefsky, ”FoxO1 haploinsufficiency protects against high-fat diet-induced insulin resistance with enhanced peroxisome proliferator-activated receptor gamma activation in adipose tissue,” Diabetes, vol. 58, no. 6, pp. 1275–1282, 2009.

[91] E. Jing, S. Gesta, and C. R. Kahn, “SIRT2 regulates adipocyte differentiation through FoxO1 acetylation/deacetylation,” Cell Metabolism, vol. 6, no. 2, pp. 105–114, 2007.

[92] H. Matsuzaki, H. Daitoku, M. Hatta, H. Aoyama, K. Yoshimochi, and A. Fukamizu, ”Acetylation of Foxo1 alters its DNA-binding ability and sensitivity to phosphorylation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 32, pp. 11278–11283, 2005.

[93] H. Daitoku and A. Fukamizu, ”FOXO transcription factors in the regulatory networks of longevity,” Journal of Biochemistry, vol. 141, no. 6, pp. 769–774, 2007.

[94] M. Ekoj, T. Kaufmann, M. Engström et al., ”The BH3-only protein puma plays an essential role in cytokine deprivation induced apoptosis of mast cells,” Blood, vol. 110, no. 9, pp. 3209–3217, 2007.

[95] C. Skurk, H. Maatz, H. S. Kim et al., ”The Akt-regulated forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP,” The Journal of Biological Chemistry, vol. 279, no. 2, pp. 1513–1525, 2004.

[96] S. D. Gopinath, A. E. Webb, A. Brunet, and T. A. Rando, ”FOXO3 promotes quiescence in adult muscle stem cells during the process of self-renewal,” Stem Cell Reports, vol. 2, no. 4, pp. 414–426, 2014.

[97] B. J. Morris, D. C. Willcox, T. A. Donlon, and B. J. Willcox, ”FOXO3: a major gene for human longevity - a mini-review,” Gerontology, vol. 61, pp. 515–525, 2015.

[98] A. van der Horst and B. M. Burgering, ”Stressing the role of FoxO proteins in lifespan and disease,” Nature Reviews Molecular Cell Biology, vol. 8, no. 6, pp. 440–450, 2007.

[99] M. M. Brent, R. Anand, and R. Marmorstein, ”Structural basis for DNA recognition by FoxO1 and its regulation by posttranslational modification,” Structure, vol. 16, no. 9, pp. 1407–1416, 2008.

[100] X. Liu, Z. Zhang, L. Sun et al., ”MicroRNA-499-5p promotes cellular invasion and tumor metastasis in colorectal cancer by targeting FOXO4 and PDCD4,” Carcinogenesis, vol. 32, no. 12, pp. 1798–1805, 2011.

[101] L. Su, X. Liu, N. Chai et al., ”The transcription factor FOXO4 is down-regulated and inhibits tumor proliferation and metastasis in gastric cancer,” BMC Cancer, vol. 14, p. 378, 2014.

[102] M. M. Xu, G. X. Mao, J. Liu et al., ”Low expression of the FoxO4 gene may contribute to the phenomenon of EMT in non-small cell lung cancer,” Asian Pacific Journal of Cancer Prevention, vol. 15, no. 9, pp. 4013–4018, 2014.